Somewhat Positive News Coverage Somewhat Unlikely to Impact Global Blood Therapeutics (GBT) Stock Price
Media stories about Global Blood Therapeutics (NASDAQ:GBT) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Global Blood Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.6855244414497 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern’s scoring:
- OncoGenex Pharmaceuticals (ACHV) vs. Global Blood Therapeutics (GBT) Head-To-Head Comparison (americanbankingnews.com)
- Three Active Stock among hottest: Global Blood Therapeutics Inc. (NASDAQ:GBT), ConocoPhillips (NYSE:COP), Kohl’s … – Market Breaking Point (press release) (journalfinance.net)
- Global Blood The Down 12.8% Since SmarTrend Downtrend Call (GBT) (mysmartrend.com)
- Calavo Growers, Inc. (NasdaqGS:CVGW), Global Blood Therapeutics Inc. (NasdaqGS:GBT) Valuation Takes Center … – Evergreen Caller (evergreencaller.com)
- Chartists Place Global Blood Therapeutics Inc. (GBT) on Notice: Technical Update – Evergreen Caller (evergreencaller.com)
Several brokerages recently issued reports on GBT. ValuEngine upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. BidaskClub upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Cowen and Company restated an “outperform” rating and issued a $83.00 price target on shares of Global Blood Therapeutics in a research report on Monday, August 14th. Oppenheimer Holdings, Inc. began coverage on Global Blood Therapeutics in a research report on Friday, August 4th. They issued an “outperform” rating and a $53.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and issued a $73.00 price target on shares of Global Blood Therapeutics in a research report on Tuesday, May 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $49.73.
Global Blood Therapeutics (NASDAQ GBT) traded up 1.78% during trading on Wednesday, reaching $28.60. The company’s stock had a trading volume of 566,579 shares. Global Blood Therapeutics has a 52 week low of $13.35 and a 52 week high of $41.15. The firm has a 50 day moving average of $27.91 and a 200 day moving average of $29.56. The stock’s market capitalization is $1.25 billion.
Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.06. During the same quarter last year, the business earned ($0.58) EPS. Analysts expect that Global Blood Therapeutics will post ($2.45) EPS for the current year.
In other news, Director Deval L. Patrick sold 27,053 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $29.69, for a total transaction of $803,203.57. Following the transaction, the director now directly owns 12,053 shares in the company, valued at $357,853.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jung Choi sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $30.00, for a total transaction of $90,000.00. Following the transaction, the insider now owns 143,255 shares in the company, valued at $4,297,650. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by corporate insiders.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.